Baek SY et al. Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial. ASCO 2022;Abstract 506.

Francis PA et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol 2022;[Online ahead of print]. Abstract

Lambertini M et al. Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy. J Natl Cancer Inst 2022;114(8):1117-26. Abstract

Pagani O et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: Long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol 2022;[Online ahead of print]. Abstract

Partridge AH et al. Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary results from the POSITIVE trial (IBCSG 48-14/BIG 8-13). SABCS 2022;Abstract GS4-09.